Key result
Pentoxifylline is a promising hemorheologic agent for the treatment of circulatory ischemic disorders, particularly intermittent claudication.
Why the study?
Does pentoxifylline improve outcomes in patients with intermittent claudication?
Does pentoxifylline improve outcomes in patients with intermittent claudication?
Pentoxifylline is highlighted as a promising hemorheologic agent for the treatment of intermittent claudication.
Answers are grounded in this paper and cite their sources.
Should not yet change practice for intermittent claudication; supports additional randomized trials of pentoxifylline.
Physiological and pathophysiological aspects of systemic and cardiac haemodynamics are reviewed with appraisal of Carl J. Wiggers merits and contributions to the research and developments in this field and his early recognition of the significance of the flow properties of blood in impaired circulation. Pharmacological agents involved in treatment of peripheral vascular diseases are discussed with special regard to the haemorheologically active xanthine derivative pentoxifylline. The profile of pentoxifylline as it emerges from experimental pharmacological and clinical studies is presented paying special attention to the haemorheological properties of the drug. Pharmacokinetic features of pentoxifylline are surveyed touching absorption, blood levels, metabolism and excretion aspects. Basing on the available data pentoxifylline is regarded as a promising drug in the treatment of circulatory ischemic disorders, especially in intermittent claudication.
No takes yet. Share an insight, caveat, or question.
Aviado et al. (1984) studied this question. Pentoxifylline is a promising hemorheologic agent for the treatment of circulatory ischemic disorders, particularly intermittent claudication.
Synapse has enriched 10 related papers. Consider them for comparative context: